People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.
The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.
During a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.
The investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.

Start Date01 Mar 2025

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT03375788 / Active, not recruitingPhase 2IIT

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.

Start Date17 Jan 2019

Sponsor / Collaborator

The General Hospital Corp.

NCT03226821 / RecruitingPhase 4IIT

Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.

Start Date07 Feb 2018

Sponsor / Collaborator

Columbia University

[+1]

100 Clinical Results associated with Tesamorelin Acetate

100 Translational Medicine associated with Tesamorelin Acetate

100 Patents (Medical) associated with Tesamorelin Acetate

Literatures (Medical) associated with Tesamorelin Acetate

01 Oct 2024·AIDS

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

Article

Author: Erlandson, Kristine M ; Fourman, Lindsay T ; Ockene, Mollie W ; Grinspoon, Steven K. ; Russo, Samuel C ; Russo, Samuel C. ; Arpante, Allison K ; Johnson, Julia E. ; Hadigan, Colleen M ; Grinspoon, Steven K ; Stanley, Takara L ; Lee, Hang ; Toribio, Mabel ; Ockene, Mollie W. ; Fourman, Lindsay T. ; Johnson, Julia E ; Stanley, Takara L. ; Hadigan, Colleen M. ; Arpante, Allison K.

Objective::

Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy.

Design::

We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo among participants on INSTI-based regimens at baseline.

Methods::

In the parent clinical trial, visceral fat cross-sectional area, hepatic fat fraction, and trunk-to-appendicular fat ratio were quantified using magnetic resonance imaging, proton magnetic resonance spectroscopy, and dual-energy x-ray absorptiometry, respectively, at baseline and 12 months. Metabolic and safety outcomes were compared between treatment arms.

Results::

Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: −25 [−93, −2] vs. 14 [3, 41] cm2, P = 0.001), hepatic fat (−4.2% [−12.3%, −2.7%] vs. −0.5% [−3.9%, 2.7%], P = 0.01), and trunk-to-appendicular fat ratio (−0.1 [−0.3, 0.0] vs. 0.0 [−0.1, 0.1], P = 0.03). Tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between groups.

Conclusions::

The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.

01 Dec 2023·Analytical biochemistry

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Article

Author: Cristea, Cătălina-Diana ; Toboc, Ani ; David, Victor ; Stan, Cristina ; Radu, Mihai

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL. The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

01 Jan 2023·Journal of clinical and translational science

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

Article

Author: Aberg, Judith A ; Potvin, Diane ; McLaughlin, Taryn ; De Chantal, Marilyn ; Rahman, Farah ; Mesquita, Pedro ; Morin, Josee

Abstract:

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VATP= 0.657, WCP= 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.

News (Medical) associated with Tesamorelin Acetate

19 Dec 2024

·endpts.com

Lonza expands capsule footprint; BioCentriq's new HQ

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza is expanding its manufacturing sites in Rewari, India, and Suzhou, China, for hard gelatin capsules, the CDMO said Thursday, despite the company flagging last week that it is looking to exit the capsule and health ingredients market. The new manufacturing lines will be online in the third quarter of 2025. BioCentriq is building a new 60,000-square-foot headquarters in Princeton, NJ, which will have cell therapy manufacturing, the CDMO said Tuesday. The factory also has potential for future clinical and commercial manufacturing expansions up to 30,000 square feet. The site will be fully operational in the second quarter of next year. Thermo Fisher Scientific is divesting its commercial samples business to Knipper Health for an undisclosed sum. Knipper will absorb Thermo Fisher’s Memphis, TN, facility as well as an undisclosed number of employees. The transaction will be completed by September 2025 and will expand Knipper’s cold chain footprint, according to a Wednesday press release. New York’s first cell and gene therapy manufacturing facility has opened at the Roswell Park Comprehensive Cancer Center in Buffalo, according to a Monday release. The factory cost $98 million to build, with $30 million from Empire State Development. Eli Lilly and EVA Pharma have won approval for their insulin glargine injection from the Egyptian Drug Authority, Lilly said Tuesday. The companies started their partnership in December 2022, with Lilly supplying APIs to EVA, who manufactures the insulin products locally. Bavarian Nordic is licensing its mpox vaccine to the Serum Institute of India under a new partnership, it announced Monday. Bavarian will allow SII to manufacture and distribute the MVA-BN vaccine in India. Valneva is also licensing its single-shot chikungunya vaccine to SII, who will manufacture and seek approval for the asset in India and other parts of Asia, according to a Thursday release. Samsung Biologics is investing , via its Life Science Fund, in the Flagship-founded company Generate:Biomedicines, according to a Wednesday release. Generate uses AI software to discover and design protein therapies. No financial details were disclosed. Celltrion has launched a new CDMO arm, dubbed Celltrion BioSolutions, the company said Tuesday. Theratechnologies has submitted a Prior Approval Supplement to the FDA outlining the changes it made to the manufacturing of its drug Egrifta, which is approved in the US to reduce belly fat in HIV and lipodystrophy patients. The FDA has four months to OK the manufacturing changes, the company said Wednesday. VaxSen has drawn support from the US International Development Finance Corporation, the African Development Bank, and the International Finance Corporation worth $45 million to improve local vaccine supply chains in Africa, according to a Tuesday release. Polyrizon has tapped the CDMO Eurofins, also called Amatsiaquitaine, to supply material for its PL-14 allergy blocker, which is entering a study next year, according to a Wednesday release. French pharma company Biocodex tapped the logistics firm Kinaxis to access its supply chain platform, according to a Monday release. BioVaxys has secured 48 kgs of lipids to start its antigen packaging platform, the company said Tuesday. The platform can package mRNA, proteins, peptides and small molecules. Moberg Pharma has secured a new manufacturer and supplier of an ingredient (terbinafine) for its nail fungus drug named MOB-015, according to a Wednesday release.

VaccineDrug ApprovalAcquisitionClinical StudymRNA

18 Dec 2024

·www.globenewswire.com

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) describing the changes made to the manufacturing environment of the facility where EGRIFTA SV® is produced. A PAS is reviewed by the FDA within four months of receipt and an approval is needed prior to the distribution of the recently manufactured batches of EGRIFTA SV®. Existing inventory levels of EGRIFTA SV® are expected to meet patient demand until mid-January 2025. Theratechnologies therefore continues discussions with the relevant FDA divisions in an effort to accelerate the release of EGRIFTA SV® and avoid a product shortage at the patient level. The Company will update the market on any further material developments. EGRIFTA SV® is distributed in the United States only. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”) within the meaning of applicable securities laws, that are based on management’s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the review period of the PAS by the FDA, the availability of EGRIFTA SV® to patients and the avoidance of an EGRIFTA SV® shortage at the patient level. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the PAS as filed will meet FDA’s regulatory requirements; (ii) the classification of the Company’s third party manufacturing site as official action indicated (OAI) will not result in the issuance of a complete response letter (CRL) following the submission of the PAS; (iii) the Company will be successful in its discussions with the various FDA divisions leading to the release of the recently manufactured batches of EGRIFTA SV® in order to avoid a drug shortage at the patient level; (iv) the FDA will review and approve the PAS before mid-January 2025; and (v) market demand for EGRIFTA SV® will remain unaffected despite the risk, or the occurrence, of a drug shortage. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) the occurrence of a drug shortage of EGRIFTA SV® due to various factors, including the inability of the Company to convince the FDA to accelerate the review timelines of the PAS or agree to alternative solutions allowing the release of the recently manufactured batches of EGRIFTA SV®, the rejection of the PAS for failure to meet regulatory requirements, the issuance of comments by the FDA on the PAS impacting its review timelines, the issuance of a CRL requiring the Company’s manufacturing site to be reinspected prior to any newly-manufactured batch of EGRIFTA SV® being released to the market; (ii) reduced revenues in the Company’s first quarter of its fiscal year 2025 in the event the PAS is not reviewed expeditiously or alternative solutions are not implemented allowing the Company to resume sales of EGRIFTA SV® before a four-month period; and (iii) patient attrition and lower demand for EGRIFTA SV® as a result of a drug shortage. The Company refers current and potential investors to the “Risk Factors” section of the Company’s annual information form filed under Form 20-F dated February 21, 2024, available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Investor inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401 Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800

Drug ApprovalAccelerated Approval

10 Dec 2024

·www.globenewswire.com

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2025 to the Company’s recently submitted supplemental Biologics License Application for the F8 formulation of tesamorelin. If approved by the FDA, the F8 formulation is intended to replace the F4 formulation, which is sold in the U.S. under the trade name EGRIFTA SV®. The new formulation is patent protected in the U.S. until 2033. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”) within the meaning of applicable securities laws, that are based on management’s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding: the time period related to the review of the sBLA by the FDA.. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the FDA will complete its review within the timelines set forth in the press release; (ii) the Company’s responses to the issues raised by the FDA in its Complete Response Letter (“CRL”) will be satisfactory to the FDA; (iii) the FDA will approve the sBLA for the F8 formulation; and (iv) if approved, health care providers and patients will adopt the F8 formulation. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) the review period of the sBLA which could be longer than the timelines set forth in this press release ;(ii) the non-approval of the sBLA by the FDA, or the issuance of another CRL; and (iii) the negative reception by the marketplace of the F8 formulation, if approved. The Company refers current and potential investors to the “Risk Factors” section of the Company’s annual information form filed under Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Investor Inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401 Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800

NDA

100 Deals associated with Tesamorelin Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tesamorelin Acetate	H01AC06	DB08869

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	US	Theratechnologies, Inc.	10 Nov 2010
Lipodystrophy	US	Theratechnologies, Inc.	10 Nov 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV-Associated Lipodystrophy Syndrome	Phase 3	US	Theratechnologies, Inc.	01 Jun 2005
HIV-Associated Lipodystrophy Syndrome	Phase 3	CA	Theratechnologies, Inc.	01 Jun 2005
Fibrosis, Liver	Phase 2	CA	Theratechnologies Europe Ltd.	30 Jan 2022
Muscular Atrophy	Phase 2	-	Theratechnologies, Inc.	01 Sep 2011
Pulmonary Disease, Chronic Obstructive	Phase 2	-	Theratechnologies, Inc.	01 Sep 2011
Diabetes Mellitus, Type 2	Phase 2	-	Theratechnologies, Inc.	01 Feb 2002
HIV Seropositivity	Phase 1	CA	Theratechnologies, Inc.	01 May 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


GlobeNewswire Manual	Phase 3	Cardiovascular Diseases \| HIV Infections	-	Tesamorelin	csxigowgec(bkyldohnig) = beyelkjdns ahslmyciix (ezdittwlhk, -0.89 to 0.05)	Positive	17 Oct 2024
ENDO2021	Not Applicable	Metabolic dysfunction-associated steatotic liver disease Maintenance C-C Motif Chemokine Ligands 3 \| interleukin-8 \| interleukin-10 ... View more	61	Tesamorelin	nxrfbftstx(gypjodczlo) = bmxzlbdmhk lykxunzapk (cphhvipbqg ) View more	Positive	03 May 2021
NCT02196831 (CTgov)	Not Applicable	Nonalcoholic Steatohepatitis \| HIV Infections	61	tesamorelin (Tesamorelin)	gymbwxxiwt(mykmpbdjbj) = jqwutxunyf tkqpjctyxr (qcmbdvgmvk, iednclrhcq - gnebopyotj) View more	-	13 Jan 2020
				Placebo (Placebo)	gymbwxxiwt(mykmpbdjbj) = qoevvpnnot tkqpjctyxr (qcmbdvgmvk, heneqpzvrw - dudrwitlej) View more
Pubmed	Phase 3	HIV Infections	806	Tesamorelin	skawuiruth(fwxfujlsfo) = wvopsvbuti neongcyjag (btvqavkfrt ) View more	-	23 Oct 2017
				Placebo	skawuiruth(fwxfujlsfo) = nrcthhzopc neongcyjag (btvqavkfrt ) View more
NCT00807365 (PP2, CTgov)	Phase 2	-	5	GHRH	stdciliacc(wdqweqdjfo) = grkyessccy zqifituvbe (upptbszunc, nnhrrtlrjq - gegeddcumi) View more	-	27 Apr 2017
NCT01263717 (CTgov)	Not Applicable	HIV-Associated Lipodystrophy Syndrome	54	tesamorelin (Tesamorelin)	heejykxikp(cknmnoouxm) = jnadyndacp umuqmijytj (weplubsawe, pxfhofmook - ivcifjqgds) View more	-	13 Oct 2014
				placebo (Placebo (Inactive Injection))	heejykxikp(cknmnoouxm) = hqrwhglulg umuqmijytj (weplubsawe, xqcmvapqmp - faejsdmpck) View more
NCT01263717 (Pubmed \| JAMA)	Not Applicable	HIV Infections	50	Tesamorelin 2 mg	mqqvpjlkds(rdhvapwyze) = bnvknwmhkh gypxrwqmec (oyvsuurfoi ) View more	-	30 Jul 2014
				Placebo	mqqvpjlkds(rdhvapwyze) = dnywpcsrgt gypxrwqmec (oyvsuurfoi ) View more
NCT01388920 (CTgov)	Phase 2	Pulmonary Disease, Chronic Obstructive \| Muscular Atrophy	3	Tesamorelin (Tesamorelin 2 mg)	rmrdeahaih(kmvjcmczkf) = teisbhvzwj ibrgjpfilj (drmgcubrch, gfzcfjigjh - gxxknzrcne) View more	-	07 May 2014
				Tesamorelin (Tesamorelin 3 mg)	rmrdeahaih(kmvjcmczkf) = sygpiyebfm ibrgjpfilj (drmgcubrch, fklljmzbqe - rqvubbnizv) View more
NCT00795210 (CTgov)	Not Applicable	Lipodystrophy \| HIV Infections	25	growth hormone (GH 6mcg/kg/d)	usuctcolis(akgwjvcdoq) = acafzjzavw wiocrjxpcu (sxijlzhbhr, wyofgywzsz - vdxracmzse) View more	-	08 Jan 2014
				growth hormone (GH 2mg Daily)	usuctcolis(akgwjvcdoq) = pdfnfgmqvx wiocrjxpcu (sxijlzhbhr, roufmdnmpp - onbyeoxhpf) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis